Indian CROs Expect To Benefit From Global Economic Angst

Clinical research organizations in India believe they are invulnerable to the impact of a recession expected to affect much of the world. In fact, new research predicts India's CRO market will triple over the next two years to a $600 million industry as large drug makers outsource more of their trials to India in the face of credit restrictions at home. The researchers noted the cost of even a simple trial in India is as much as 20 percent cheaper than in the United States, with the most complex ones saving more than half the U.S. cost. (Click here for more